证券代码：002773 证券简称：康弘药业 公告编号：2025-073 成都康弘药业集团股份有限公司 关于注销部分募集资金专用账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 1、首次公开发行股票募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）"证监 许可[2015]1198号文"核准，成都康弘药业集团股份有限公司（以下 简称 "公司"）公开发行人民币普通股股票4,560.00万股，每股发 行价为13.62元，扣除证券公司承销费、保荐费等费用后实际募集资 金净额为人民币57,624.77万元。上述募集资金已于2015年6月23日全 部到位，经信永中和会计师事务所（特殊普通合伙）审验，并出具了 XYZH/2015CDA50084号《验资报告》。 2、公开发行可转换公司债券募集资金基本情况 经中国证监会（证监许可[2019]2572号）核准，公司公开发行了 1,630.00万张可转换公司债券，每张面值100元，发行总额163,000.00 万元，扣除证券公司承销费、保荐费等费用后实际募集资金净额为人 民币160, ...

康弘药业公告称，公司首次公开发行股票实际募资净额5.76亿元，公开发行可转债实际募资净额16.09亿 元，均实行专户存储管理。鉴于"康弘药业固体口服制剂异地改扩建项目"已建设完毕，公司于2025年12 月23日将该项目募集资金专户（账号：118535908070）余额113.31万元转入基本户并永久补充流动资 金，办理完成销户手续，项目剩余尾款/质保金将用自有资金支付，相关监管协议相应终止。 ...

Group 1 - The core viewpoint emphasizes that listed companies in China are not only the main force behind data growth but also serve as a stabilizing factor in the industry ecosystem, focusing on long-term value and comprehensive governance [2] - In 2025, the capital market aims for steady progress and quality improvement amidst multiple risks, enhancing market resilience and risk resistance, leading to reasonable quantitative growth and effective qualitative enhancement [2] - The market's expectations for listed companies have shifted from short-term performance to long-termism and comprehensive value, including governance structure, stable returns, strategic layout in frontier fields, and deep ESG practices [2] Group 2 - The 2025 T-EDGE Global Dialogue, organized by Titanium Media Group, NextFin.AI, and Barron’s China, highlights the importance of recognizing companies that redefine industry boundaries and emphasizes the core logic of "value investment" [3] - The EDGE AWARDS annual list includes categories such as Most Socially Responsible Company, Best Board Secretary, Most Investment Value Company, and Best Investor Relations Management Company, recognizing outstanding performance in governance, investment value, social responsibility, and investor relations [3][4] Group 3 - Aier Eye Hospital is recognized as a leader in ESG practices, integrating ESG into its core business and governance structure, while actively engaging in public welfare projects to enhance national eye health [5] - Betaini Group focuses on creating a skin health ecosystem and incorporates green development into its strategy, promoting biodiversity and sustainable practices [6] - Kweichow Moutai leads the liquor industry with a brand value of 468.718 billion, actively engaging in ecological protection and social responsibility initiatives [7] - JD Group has created significant employment opportunities and is committed to improving living conditions for its delivery personnel, with plans to invest 22 billion in housing projects [8] - Quantitative Group, listed on the Hong Kong Stock Exchange, leverages AI technology to reshape online consumption and has achieved a compound annual growth rate of 44.59% in revenue from 2022 to 2024 [9] - Seres focuses on new energy vehicles and has established a robust ESG governance framework, with significant growth in revenue and sales projected for 2024 [10] - Shui Jing Fang integrates social responsibility into its corporate strategy, setting clear environmental goals and contributing to community development [11] - China Baoan actively engages in social responsibility through its subsidiaries, contributing to community welfare and healthcare improvements [13] Group 4 - The Best Board Secretary category highlights the importance of effective communication between listed companies and the public, emphasizing the role of board secretaries in enhancing corporate governance [14] - Ren Shunying from Anfu Technology is recognized for her expertise in capital operations and corporate governance, significantly contributing to the company's compliance and investor relations [15] - Xia Ping from Jiahe Intelligent is noted for her effective investor relations management and participation in strategic planning [16] - Li Liangyu from Robotech is acknowledged for his role in maintaining corporate governance and enhancing market recognition [17] - Zhang Wenyu from Tianqi Lithium is recognized for his contributions to market value management and investor relations [18] Group 5 - The Most Investment Value Company category identifies companies with clear business models and significant breakthroughs in technology or policy, indicating strong growth potential [19][20] - Orbbec, a leader in 3D vision technology, has achieved over 70% market share in key sectors and continues to lead industry advancements [20] - BYD maintains its position as a global leader in new energy, with significant growth in overseas markets and a strong investment outlook [21] - Cambrian has entered a critical profitability phase, with substantial revenue growth and a strong market position in AI chips [22] - Hanlan Environment focuses on environmental services and has achieved consistent profit growth, attracting long-term investors [23] - Geely Auto has demonstrated strong financial performance and strategic integration, positioning itself for sustained growth [24] - Kanghong Pharmaceutical emphasizes innovation in drug development and has shown robust revenue growth, indicating long-term investment value [25] - Lens Technology maintains a strong market position with solid cash flow and growth potential in the automotive and consumer electronics sectors [26]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002773 证券简称：康弘药业 公告编号：2025-070 成都康弘药业集团股份有限公司 二〇二五年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、现场会议召开时间：2025年12月19日（星期五）10:30。 2、现场会议召开地点：成都尊悦豪生酒店（成都市金牛区迎宾大道528号）。 3、会议召开与投票方式：本次股东会采用现场表决与网络投票相结合的方式召开。其中：通过深圳证 券交易所交易系统进行网络投票的具体时间为2025年12月19日9:15一9:25，9:30一11:30和13:00一 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年12月19日9:15-15:00。 4、召集人：成都康弘药业集团股份有限公司（以下简称"公司"）董事会。 5、主持人：董事长柯尊洪先生。 6、会议的召集、召开与表决程序符合《中华人民共和国公司法》《上市公司股东会规则》《深圳证券 交易所股票上市规则》及《公司章程》等法律、法规、规范性文件及公司制度的规定 ...

（文章来源：证券日报） 证券日报网讯 12月19日晚间，康弘药业发布公告称，公司第八届董事会第十五次会议审议通过《关于 补选公司第八届董事会战略委员会委员的议案》。 ...

证券日报网讯12月19日晚间，康弘药业（002773）发布公告称，公司2025年第一次临时股东会审议通过 《关于变更公司注册资本及修订 <公司章程> 的议案》《关于修订公司部分内部制度的议案》《关于修 订 <募集资金管理制度 年12月="年12月"> 的议案》等多项议案。 ...

成都康弘药业集团股份有限公司（以下简称"公司"）董事会于 今日收到公司董事殷劲群先生提交的书面辞职报告，为全面贯彻落实 最新法律法规要求，推进公司治理结构优化工作，殷劲群先生因公司 治理结构调整自愿辞去公司董事、董事会战略委员会委员职务，辞职 后，殷劲群先生将继续在公司及下属企业担任其他职务。殷劲群先生 的辞职报告自送达董事会时生效。 证券代码：002773 证券简称：康弘药业 公告编号：2025-071 成都康弘药业集团股份有限公司 关于公司董事辞职暨选举职工代表董事、 补选战略委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事辞职情况 本次选举职工代表董事工作完成后，公司董事会中兼任高级管理 人员以及由职工代表担任的董事人数，总计未超过公司董事总数的二 分之一，符合相关法律法规的规定。 三、关于补选董事会专门委员会成员的情况 截至本公告披露日，殷劲群先生持有公司股票 351,350 股，占公 司总股份的 0.04%。后续殷劲群先生将遵守《深圳证券交易所上市公 司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》 《深圳证 ...

2025年1至6月份，康弘药业的营业收入构成为：医药制造业占比99.97%，其他业务占比0.03%。 （记者 贾运可） 截至发稿，康弘药业市值为285亿元。 每经AI快讯，康弘药业（SZ 002773，收盘价：30.98元）12月19日晚间发布公告称，公司第八届第十五 次董事会会议于2025年12月19日在公司会议室通过现场和通讯相结合的方式召开。会议审议了《关于补 选公司第八届董事会战略委员会委员的议案》等文件。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ ...

中国成都市高新区天府一街 535 号两江国际 B 栋 33 层 61000 33/F, Building B, Twin Rivers International, No.535 Tianfu 1st Street, High-tech District, Chengdu 610000, China 电话 Tel: +86 28 6753 5588 传真 Fax: +86 28-6753 5588 电邮 Email: chengdu@tongshang.com 网址 Web: www.tongshang.com 北京通商(成都)律师事务所 关于成都康弘药业集团股份有限公司 二〇二五年第一次临时股东会之 法律意见书 致：成都康弘药业集团股份有限公司 北京通商(成都)律师事务所(以下简称"本所")接受成都康弘药业集团股份 有限公司(以下简称"公司")的委托，委派喻丹律师、周宇欣律师出席公司二〇 二五年第一次临时股东会(以下简称"本次股东会")，并根据《中华人民共和国 公司法》(以下简称"《公司法》")、《中华人民共和国证券法》等中国法律、法 规及规范性文件(以下简称"相关法律、法规"，为本法律意见书之目的，"中国 ...